Eli Lilly Ranks High in Growth Investment Strategies

Eli Lilly shines with an 88% rating in a growth model analysis. This demonstrates strong potential for investors as the stock shows positive underlying fundamentals.

Date: 13-03-2025

AI Rating: 7

Investment Potential of Eli Lilly

Eli Lilly and Co (LLY), classified in the Biotechnology & Drugs industry, has received an impressive rating of 88% based on the growth model used from the P/B Growth Investor strategy. This suggests a favorable outlook as a potential investment. The report indicates that a score above 80% reflects some interest from the strategy, while ratings above 90% signify strong interest.

The analysis assesses several metrics that were highlighted as strengths:

**Book/Market Ratio**: PASS
**Return on Assets**: PASS
**Cash Flow from Operations to Assets**: PASS
**Cash Flow from Operations to Assets vs. Return on Assets**: PASS
**Return on Assets Variance**: PASS
**Sales Variance**: PASS
**Advertising to Assets**: PASS
**Capital Expenditures to Assets**: PASS

These positive metrics indicate that Eli Lilly maintains healthy operations and efficiency regarding asset management. However, there is one area of concern:

**Research and Development to Assets**: FAIL

This failure suggests that Eli Lilly may be falling short in its investments towards research and development, which could potentially affect its innovation and long-term growth. Nonetheless, the wealth of positive metrics outweighs this concern, making Eli Lilly a favourable candidate for growth investment.

Stocks: LLY